Is anti-TNF switching in refractory Still’s disease safe and effective?
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Nadia Emi Aikawa & Ana Cristina de Medeiros Ribeiro & Carla Gonçalves Schain Saad & Rosa Maria Rodrigues Pereira & Mauricio Levy & Clovis A. Silva & E
- چاپ و سال / کشور: 2011
Description
Still’s disease (SD) is a rare chronic inflammatory disease characterized by polyarthritis, systemic symptoms, and elevated inflammatory markers. Of note, 74 SD cases were reported with anti-tumoral necrosis factor (TNF) therapy and the experience of switching is limited to five patients. During a 3-year period, SD cases were 1.9% of 319 rheumatic patients that received anti-TNF agents in the infusion center of our University Hospital. In this manuscript, the authors add six new cases of refractory SD who had clinical and laboratory response to TNF blockers and report the outcome of switching in five of them. Partial or complete response was achieved by four of six (66.7%) patients and three of four (75%) required switching. Regarding safety, five of six (83.3%) had adverse events. Anti-TNF treatment with switching seems to be a valid approach for refractory SD patients.
Clin Rheumatol (2011) 30:1129–1134 Received: 5 November 2010 / Revised: 7 January 2011 / Accepted: 7 March 2011 / Published online: 5 April 2011
